Starling Oncology vs U S Physical Therapy
U S Physical Therapy is the larger business, with $781m of revenue in fiscal 2025 against $503m for Starling Oncology (1.6 times as much). Starling Oncology grew faster (27.8% against 16.3%). U S Physical Therapy kept more of each dollar of sales as profit: a net margin of 5.1% against -12.1%.
| Latest fiscal year | Starling OncologySTLN, 2025 | U S Physical TherapyUSPH, 2025 |
|---|---|---|
| Revenue | $503m | $781m |
| Revenue growth | 27.8% | 16.3% |
| Net income | −$60.6m | $39.6m |
| Operating margin | — | 11.1% |
| Net margin | -12.1% | 5.1% |
| Return on equity | — | 8.2% |
| Free cash flow | −$27.8m | $61.0m |
| Cash | $33.6m | $35.6m |
| Total debt | $85.9m | $162m |
| Debt to equity | — | 34.1% |
| Dividend per share | — | $1.80 |
| Dividend yield | — | — |
| Share buybacks | — | $5.6m |
| Employees | 641 | 7,294 |
| Market value | $633m | $1.29bn |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | 46 (Moderate) |
| Insider trades, 12 months | 16 buys, 11 sales | 5 buys, 5 sales |